Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Congestive Heart Failure Receiving Therapy for Breast Cancer

Launched by NATIONAL CANCER INSTITUTE (NCI) · Nov 19, 2015

Keywords

ClinConnect Summary

This clinical trial is looking at how changes in genes might affect patients with congestive heart failure (CHF) who are also undergoing treatment for breast cancer. Researchers will analyze DNA samples from patients to find specific genetic variations that could help explain why some people develop CHF while receiving certain cancer therapies. By understanding these genetic changes, doctors hope to identify markers that could indicate a higher risk for CHF in breast cancer patients.

To participate in this study, you need to be either European American with available DNA samples or African American with specific heart function measurements. Participants will provide their DNA and may help researchers learn more about the connection between cancer treatments and heart health. This study is currently recruiting and is open to all genders. If you’re interested in helping advance knowledge in this area, this trial may be a valuable opportunity for you.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • European American patients with DNA available
• • European American patients who developed CHF and patients who did not develop CHF following a full course of treatment with an anthracycline and bevacizumab
• • African American cases (based on a drop in left ventricular ejection fraction \[LVEF\] \< 50 or a drop from baseline \> 20 points) and African American controls